308 A randomized, double-blind, phase 2 study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib vs pembrolizumab plus lenvatinib in patients with previously treated mismatch repair-proficient advanced endometrial cancer
308 A randomized, double-blind, phase 2 study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib vs pembrolizumab plus lenvatinib in patients with previously treated mismatch repair-proficient advanced endometrial cancer